Skip to main content
Journal cover image

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.

Publication ,  Journal Article
Secord, AA; Darcy, KM; Hutson, A; Lee, PS; Havrilesky, LJ; Grace, LA; Berchuck, A; Gynecologic Oncology Group study,
Published in: Gynecol Oncol
July 2007

OBJECTIVES: The aim of this study was to explore the co-expression and prognostic relevance of thrombospondin-1 (THBS-1), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR-1) in epithelial ovarian cancer (EOC). METHODS: Frozen tumor specimens with defined p53 status were obtained from 67 patients with previously untreated advanced-stage EOC who participated in a Gynecologic Oncology Group specimen-banking protocol and a phase III treatment protocol. Relative expression of the angiogenic markers was quantified by immunoblot analysis and categorized at the median angiogenic marker/actin ratio. p-values are provided as an indication of confidence in the results and to prioritize further testing. RESULTS: An association was observed between categorized VEGF and p53 overexpression (p=0.022), and between VEGFR-1 and race (p=0.027) or histologic subtype (p=0.007). Unadjusted Cox regression analyses indicated that high compared with low THBS-1, but not VEGF or VEGFR-1, was associated with an increased risk of disease progression (hazard ratio [HR]=2.19; 95% confidence interval [CI]=1.29-3.71; p=0.004) and death (HR=1.93; 95% CI=1.12-3.32; p=0.018) whereas bFGF was associated with a reduced risk of disease progression (HR=0.60; 95% CI=0.36-0.99; p=0.046) and death (HR=0.54; 95% CI=0.32-0.93; p=0.026). After adjusting for prognostic factors including clinical characteristics and p53 overexpression, THBS-1 but not bFGF, VEGF or VEGFR-1 was associated with progression-free and overall survival. CONCLUSIONS: These data suggest that high THBS-1 is an independent predictor of worse progression-free and overall survival in women with advanced-stage EOC. A larger prospective study is warranted for validation of these findings.

Duke Scholars

Published In

Gynecol Oncol

DOI

ISSN

0090-8258

Publication Date

July 2007

Volume

106

Issue

1

Start / End Page

221 / 232

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A
  • Thrombospondin 1
  • Survival Rate
  • Retrospective Studies
  • Proportional Hazards Models
  • Prognosis
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Darcy, K. M., Hutson, A., Lee, P. S., Havrilesky, L. J., Grace, L. A., … Gynecologic Oncology Group study, . (2007). Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 106(1), 221–232. https://doi.org/10.1016/j.ygyno.2007.03.021
Secord, Angeles Alvarez, Kathleen M. Darcy, Alan Hutson, Paula S. Lee, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Andrew Gynecologic Oncology Group study. “Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol 106, no. 1 (July 2007): 221–32. https://doi.org/10.1016/j.ygyno.2007.03.021.
Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):221–32.
Secord, Angeles Alvarez, et al. “Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.Gynecol Oncol, vol. 106, no. 1, July 2007, pp. 221–32. Pubmed, doi:10.1016/j.ygyno.2007.03.021.
Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Gynecologic Oncology Group study. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):221–232.
Journal cover image

Published In

Gynecol Oncol

DOI

ISSN

0090-8258

Publication Date

July 2007

Volume

106

Issue

1

Start / End Page

221 / 232

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A
  • Thrombospondin 1
  • Survival Rate
  • Retrospective Studies
  • Proportional Hazards Models
  • Prognosis
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic